Purpose: To analyse the factors predicting uncontrolled seizures in epilepsy with auditory features (EAF). Methods: We analysed individual data from EAF patients who were previously reported. Two authors independently reviewed the titles and abstracts identified and extracted data from each eligible study using a standardized form. The outcome measure was uncontrolled seizures. The odds ratio (OR) and 95% confidence interval (CI) were used. Results: A total of 27 studies including 181 patients with familial and sporadic EAF met our inclusion criteria. None of the clinical factors appeared to affect seizure outcomes significantly except that treatment with carbamazepine was a protective factor against uncontrolled seizures (OR = 0.399, 95% CI: 0.195-0.820, p = 0.012), and polytherapy was associated with uncontrolled seizures. Treatment with carbamazepine was also a protective factor against uncontrolled seizures for families with LGI1 mutations (OR = 0.248, 95% CI: 0.085-0.724, p = 0.011). Carbamazepine might have a better efficacy in patients with frequent seizures (p = 0.041). Low-dose carbamazepine might completely control seizures in some EAF patients, although other effective doses of antiepileptic drugs might not. Patients without carbamazepine treatment were more likely to use new antiepileptic drugs, which might be due to the higher rate of uncontrolled seizures. Conclusions: Carbamazepine treatment is a protective factor against uncontrolled seizures for EAF. However, this evidence is not strong enough to state that carbamazepine is the first choice drug for EAF.
Introduction
Epilepsy with auditory features (EAF) is a heterogeneous clinicomolecular syndrome, with or without bilateral tonic-clonic seizures, featured by seizures with auditory symptoms suggesting lateral temporal-lobe origin [1, 2] . The aetiology underlying EAF is considered to be associated with specific genes because autosomal-dominant EAF has been reported extensively, and mutations mainly in the leucine-rich glioma-inactivated protein 1 (LGI1) gene were detected [3, 4] . About 50% of autosomal-dominant EAF families and < 2% of sporadic cases have LGI1 gene mutations [5] . EAF has been proposed as a benign epilepsy syndrome with good seizure outcome. However, a recent study showed a less favourable outcome than previous studies, with only 34% of the EAF patients realizing five seizure-free years [1] . Treatment of EAF still seems to be difficult.
Identification of the predicting factors of uncontrolled seizures is the first step to improve the outcomes of EAF. However, EAF is a relatively rare epilepsy syndrome. It is difficult to conduct a study with a large sample to identify predicting factors because of its low prevalence. Therefore, the current study used meta-analytic methods to pool available data to investigate predicting factors of uncontrolled seizures in EAF. We expected that this meta-analysis would indicate one or more risk factors that could provide an intervention point to decrease the uncontrolled seizure rate.
Inclusion and exclusion criteria
Studies were included if they (1) were published in English and the full text could be obtained, (2) included familial or sporadic EAF patients with and without a mutation and (3) reported whether treatments were accepted. Studies were excluded if they (1) were meeting abstracts, reviews, letters and erratum, (2) focused on autoimmune encephalitis and other diseases, (3) were animal and basic studies, (4) were unclear about the use of antiepileptic drugs (AEDs), (5) did not document seizure outcomes and (6) repeated data. If there was any disagreement about article selection, they would be resolved through discussion among all the authors.
Diagnosis criteria and outcomes measure
The diagnosis criteria of EAF were the occurrence of at least two lifetime seizures preceded by auditory or aphasic aura and a negative family history for epilepsy in firstand second-degree relatives (sporadic cases) [6] and a positive family history for EAF, with or without auditory aura (familial cases). Auditory auras were classified as seizures. If patients had a history of only febrile seizures but not epilepsy, they were excluded. We chose uncontrolled seizures as an outcome measure. Uncontrolled seizures was defined by ongoing seizures, with or without AEDs treatment, which was indicated by authors in the included articles. If authors indicated that a patient was seizure-free, this patient would not be classified into groups with uncontrolled seizure even though the duration of seizure freedom was not addressed.
Data extraction
Data were collected in Microsoft ® Excel ® . Data about repeatedly reported families were recorded once. Two authors (Lin Zhang and Xi Zhu) searched and screened the titles, abstracts and full-text articles independently. The same two reviewers independently extracted relevant information from each eligible study, using a standardised form. The first author, date of publication and country, gender, age, symptoms of seizures, onset age of seizures, ethnicity, family ID, number of affected participants in family, abnormal gene and chromosome, generation, type of seizure (only focal seizures, with or without bilateral tonic-clonic seizures and convulsive seizures), frequency at seizure onset or until onset of treatment, previous and current AEDs, seizure outcomes (uncontrolled seizures or not), neuroimaging results and interictal electroencephalogram (EEG) patterns were recorded according to the included studies. If patients with different AEDs and with uncontrolled seizures were seizure free on one or more certain AEDs in the past was also recorded.
Standard protocol approvals, registrations, and patient consents
This work was performed based on published studies, so no approvals, registrations or informed consent were required.
Statistical analysis
Considering that the use of AEDs is an important factor in seizure outcomes, patients were not included in the analysis if (1) they used AEDs irregularly or they were not compliant, (2) whether AEDs were used was unclear and (3) the number of used AEDs was unclear. All analyses were based on the individual data from familial and sporadic EAF patients. Continuous variables were presented as mean ± standard deviation (SD). The two-tailed, unpaired t-test was used to compare continuous variables. Categorical variables were compared using the χ 2 test or Fisher's exact test. Logistic regression analyses were used to estimate adjusted odds ratios (OR) and 95% confidence interval (CI). In logistic regression analyses, factors were mainly selected according to a p-value < 0.10 in univariate analysis, and patients with missing data were excluded. P < 0.05 was determined to be statistically significant. Statistics were performed using SPSS (version 20.0).
Results

Study identification and selection
The selection process is shown in Fig. 1 . After removing duplicates, 624 titles and abstracts were screened. Full-text screenings were performed on 72 articles. Forty-six articles were removed, and the reasons are shown in Fig. 1 . A total of 27 studies, including 204 patients with familial or sporadic EAF, met our inclusion criteria [3, 4, . However, 23 patients were excluded because of unclear or irregular use of AEDs. Finally, 181 patients were included in the analysis. The characteristics of the included studies are presented in Table 1 . All included families or sporadic cases had at least one difference in the following items: ethnicity, mutations, medical institutions and pedigree. No families or sporadic cases were duplicated. There were 29 patients with different AEDs and with uncontrolled seizures. Twenty-five of those patients used a combination drug regimen according to the authors' statements. Authors did not indicate that any of the patients with different AEDs and uncontrolled seizures were seizure free on certain AEDs in the past.
Univariate analysis and logistic regression analysis
The clinical features of the included population and univariate analysis with comparison of the clinical features between uncontrolled seizures and seizure remission (SR) groups are listed in Table 2 . Some factors (generation of patients, multiple AEDs, treatment without carbamazepine (CBZ), and only treatment with new AEDs) tended to be associated with uncontrolled seizures. In logistic regression analysis, none of the clinical factors appeared to affect seizure outcomes significantly except that treatment with CBZ was a protective factor against uncontrolled seizures (adjusted OR = 0.399, 95% CI: 0.195-0.820, p = 0.012, see Table 3 ), and polytherapy was associated with uncontrolled seizures (adjusted OR = 4.111, 95% CI: 1.928-8.763, p < 0.001).
Comparison between groups with and without CBZ for predicting factors of uncontrolled seizures
In the past, CBZ was the first choice in focal epilepsy. Therefore, a bias toward carbamazepine might exist. To verify this question, we compared baseline characteristics of predicting factors, which were chosen from Table 2 , between groups with and without CBZ treatment. There were no significant differences for most factors, except that patients with CBZ treatment were younger than those without CBZ treatment ( Table 1 ). The possible reason was that phenobarbital (PB) and phenytoin (PHT) were used earlier than CBZ. Patients without CBZ treatment were also more likely to use new AEDs, which may be due to the higher rate of uncontrolled seizures. In EAF patients who were treated with traditional AEDs, the first drugs were not only CBZ (< 54/ 61) but also valproic acid (VPA), PB or PHT (> 58/65). The first drugs in seven patients could not be identified. There was no strong bias toward carbamazepine (p = 1.000).
CBZ for EAF patients with frequent seizures
The clinical features of EAF patients with frequent seizures are presented in Table 4 . Fourteen EAF patients were treated with CBZ and 13 EAF patients were treated with other traditional AEDs or oxcarbazepine (OXC). CBZ might have a better efficacy than other traditional AEDs for frequent seizures (p = 0.041). In addition, two patients with monthly seizures became seizure-free when VPA was changed to CBZ [15] . Another two patients were also free from seizures when PB and PHT were changed to CBZ [27] .
Doses of CBZ and SR
The doses of 10 EAF patients treated with CBZ alone were described, and one of them still had seizures. Five of them used CBZ 400 mg/day, below the 50% WHO defined daily dose (DDD), and none of these five individuals had seizures. The doses of 27 EAF patients treated with other AEDs were described. Only one of them used a dose below the 
Predicting factors of uncontrolled seizures in LGI1-associated epilepsy
We performed a comparison of the clinical features and a logistic regression analysis for families with LGI1 mutations (Tables 2 and 3) to predict uncontrolled seizures. Some factors (generation of patient, multiple AEDs and treatment without CBZ) tended to be associated with uncontrolled seizures. In the logistic regression analysis, none of the clinical factors appeared to affect seizure outcomes significantly, except that treatment with CBZ was a protective factor against uncontrolled seizures (adjusted OR = 0.248, 95% CI: 0.085-0.724, p = 0.011, see Tables 3), and polytherapy was associated with uncontrolled seizures (adjusted OR = 4.097, 95% CI: 1.492-11.255, p = 0.006).
Discussion
In the present study, the focus was on the prognostic factors for uncontrolled seizures in EAF. The main findings of the study were as follows: (1) Most factors, such as gender, age, LGI1 mutation and interictal EEG patterns, did not appear to affect seizure outcomes significantly. (2) EAF patients with uncontrolled seizures used more new AEDs. (3) EAF patients with uncontrolled seizures were more likely to be treated without CBZ. (4) CBZ might be more effective than other traditional AEDs for EAF patients with frequent seizures. (5) Low-dose CBZ might completely control seizures in some EAF patients.
AEDs are the most common forms of treatment for EAF. The current literature provides little valuable evidence for choice of AEDs for patients with EAF. We noticed that VPA with the trough blood level of 62-70 mg/L could not control the focal seizures in patients with familial EAF. However, the patients were free from seizures when VPA was changed to CBZ 500 mg/day [15] . CBZ completely suppressed seizures in seven of 11 patients with sporadic EAF, whereas only six of 21 patients had SR from using other AEDs [6] . CBZ also had a higher rate of SR in familial focal epilepsy with markers on 10q than VPA did [12, 31] . In this study, we also found that seizures were not more likely to be controlled if patients were not treated with CBZ. In addition, CBZ might be more effective than other traditional AEDs for EAF patients with frequent seizures. Low-dose CBZ might completely control seizures in partial EAF patients, although other effective-dose AEDs might not. Therefore, it was reasonable to assume that CBZ provided better control of seizures than VPA, PHT or PB for EAF. For new AEDs, there was not enough data to draw the conclusion that CBZ was superior. Patients who were also treated with new AEDs were more likely to have uncontrolled seizures, this was presumably because their physicians might prescribe new AEDs if traditional AEDs failed.
There are some possible explanations for the significant advantages of CBZ in efficacy. About 50% of EAF cases are induced by LGI1 dysfunction, which is different from other seizures because of differing pathophysiologic processes. LGI1, as a secretory protein binding to ADAM22/23, regulates intrinsic excitability by postsynaptic density protein-95 (PSD-95) and Kv1 channels [32, 33] . Low expression of PSD-95 greatly decreases AMPA receptor-mediated synaptic transmission in wild-type neurons [34] . Reduced AMPA receptor function on inhibitory thalamic neurons causes disinhibition of the thalamocortical network and contributes to seizures [32] . CBZ can significantly increase PSD-95 levels in a cytotoxicity model [35] . Therefore, CBZ may recover the abnormal intrinsic excitability induced by the loss of LGI1 function. On the other hand, LGI1 regulates neuronal excitability by setting the density of Kv1 channels. Abnormal Kv1 expression results in disinhibition of glutamate release, which is considered the basis of abnormal neuronal excitability [33] . CBZ, as a sodium channel blocker, can reduce this effect via various mechanisms, such as inhibiting Na + channel-mediated glutamate release but not necessarily the Kv1 expression [36] [37] [38] . Therefore, CBZ may have the capacity to inhibit abnormal neuronal excitability in LGI1-associated epilepsy. A few patients with sound-induced seizures in EAF families were reported [8, 16, 27] . Some researchers also thought that auditory auras and seizures sometimes triggered by noises or voices, although a specific percentage was not provided [39, 40] . This was why they tried to prove that auditory stimuli induce seizures at a lower threshold in LGI1 knockout mice, which reflected the human pathology of sound-triggered seizures in some EAF patients [40] . Previous studies provided evidence that chronic CBZ therapy had a suppressive effect on the auditory pathways through the central and peripheral structures of the auditory system [41] [42] [43] . It is well known that the auditory pathway ends at the cortex of the temporal lobe. Therefore, CBZ might counteract the effect of the lowered seizure threshold and suppress the initiation process of auditory-triggered seizures in EAF patients with sound-induced seizures. However, most patients with EAF do not have sound-induced seizures. The discussion above may not reflect most situations. The mechanisms as to how CBZ may influence outcome in EAF patients merits further study.
This study has clinical significance. More than 15 AEDs can be used for adults and children with focal seizures. However, focal epilepsy is a heterogeneous disease because of different aetiologies such as genetic, structural, metabolic, autoimmune, and infectious causes. People who suffer from focal seizures with different causes respond quite differently to the same drug. Therefore, precision medicine for focal seizures with different causes is necessary, and EAF is not an exception. The most important significance of our study is that it may provide a more accurate choice for EAF. In addition, EAF patients with high seizure frequency at onset had a lower SR rate than those with low seizure frequency at onset [1] . CBZ may have a better efficacy than other AEDs against frequent seizures. More interesting, seizures can be completely controlled in some patients even if the doses of CBZ are below the 50% DDD; therefore, dose-dependent side effects and treatment costs are less than with other AEDs. After performing more studies with large samples, CBZ may be the first choice for EAF patients.
The present study has several limitations. First, no ideal data collection could be performed. For example, we only searched for English literature in two electronic databases. Second, a statistical analysis had to be performed by relying only on the included studies. However, this might result in less-accurate results because of selective reports and incomplete data. Third, the number of studies and patients included was insufficient for part of the results. Fourth, 4 patients with different AEDs and with uncontrolled seizures might not use a combination drug regimen. It was unclear if any of them were seizure free on certain AEDs, and these might have been stopped. However, we thought that the results were unlikely to be affected by a few patients. These results should be interpreted carefully. A random controlled trial with a large sample is needed for further study.
Conclusion
Our study supports the hypothesis that CBZ treatment is a protective factor against uncontrolled seizures for EAF. Our study was based only on the individual patient data from published literature, which limited the reliability of results. Random controlled trials with large samples are required to verify this finding. Further studies of the mechanisms underlying the therapeutic efficacy of CBZ may be helpful in revealing molecular pathways and the discovery of new treatments for EAF.
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